38 , 39 In the STRIVE study, while there was no difference between sivelestat and placebo in terms of all-cause 28-day mortality, a negative trend in long-term (180-day) mortality prompted the Data and Safety Monitoring Board to recommend suspension of enrollment and discontinuation of the study.
← all excerpts
Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome.
1
—
—